The United Bio-Technology (Hengqin) Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-35
RECRUITING4
READOUTS ≤12 MONTHS3
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| MASH NCT07145151 |
P2 | Recruiting | Metabolic Dysfunction-associated Steatohepatitis (MASH) | 156 | 2027-06-04 |
| UNIGUIDE-1 NCT07659574 |
P3 | Recruiting | Type 2 Diabetes | 360 | 2027-09-24 |
| UBT251 Injection 4.0 mg NCT07648225 |
P3 | Active, not recruiting | Obesity & Overweight | 600 | 2027-09-29 |
| UNIGUIDE-2 NCT07653477 |
P3 | Recruiting | Type 2 Diabetes | 956 | 2028-02-29 |
| UNISHAPE-OSA-1 NCT07767942 |
P3 | Not yet recruiting | Obstructive Sleep Apnea, Obesity | 150 | 2028-09 |
| UNISHAPE-OSA-2 NCT07806851 |
P3 | Not yet recruiting | Obstructive Sleep Apnea; Obesity | 150 | 2029-03 |
| UBT251 NCT07134335 |
P2 | Recruiting | Obesity &Amp; Overweight; Chronic Kidney Disease | 180 | 2030-07-11 |